登录 | 注册    关注公众号  
微信公众号
搜索
 >  Antibody>A17L (MPXV) >A1L-M698

Monoclonal Anti-Monkeypox virus (strain Zaire-96-I-16) A17L Antibody, Human IgG1 (1B4)

抗体来源(Source)

Monoclonal Anti-Monkeypox virus (strain Zaire-96-I-16) A17L Antibody, Human IgG1 (1B4) is a chimeric monoclonal antibody recombinantly expressed from HEK293, which combines the variable region of a mouse monoclonal antibody with Human constant domain.

克隆号(Clone)

1B4

亚型(Isotype)

Human IgG1 | Human Kappa

偶联(Conjugate)

Unconjugated

抗体类型(Antibody Type)

Recombinant Monoclonal

种属反应性(Reactivity)

Virus

免疫原(Immunogen)

Recombinant Monkeypox virus (strain Zaire-96-I-16) A17L Protein is expressed from human 293 cells.

特异性(Specificity)

Specifically recognizes Monkeypox virus (strain Zaire-96-I-16) A17L.

应用(Application)

ApplicationRecommended Usage
ELISA0.06-15 ng/mL 

纯度(Purity)

>90% as determined by SDS-PAGE.

纯化(Purification)

Protein A purified / Protein G purified

制剂(Formulation)

Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

Contact us for customized product form or formulation.

重构方法(Reconstitution)

Please see Certificate of Analysis for specific instructions.

For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

存储(Storage)

For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Please avoid repeated freeze-thaw cycles.

This product is stable after storage at:

  1. -20°C to -70°C for 12 months in lyophilized state;
  2. -70°C for 3 months under sterile conditions after reconstitution.

质量管理控制体系(QMS)

  1. 质量管理体系(ISO, GMP)
  2. 质量优势
  3. 质控流程
 

电泳(SDS-PAGE)

A17L (MPXV) SDS-PAGE

Monoclonal Anti-Monkeypox virus (strain Zaire-96-I-16) A17L Antibody, Human IgG1 (1B4) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With Star Ribbon Pre-stained Protein Marker).

 

活性(Bioactivity)-ELISA

A17L (MPXV) ELISA

Immobilized Monkeypox virus (strain Zaire-96-I-16) A17L Protein, His Tag (Cat. No. A1L-M52H3) at 1 μg/mL (100 μL/well) can bind Monoclonal Anti-Monkeypox virus (strain Zaire-96-I-16) A17L Antibody, Human IgG1 (1B4) (Cat. No. A1L-M698) with a linear range of 0.06-2 ng/mL (QC tested).

Protocol

 

活性(Bioactivity)-SPR

A17L (MPXV) SPR

Monoclonal Anti-Monkeypox virus (strain Zaire-96-I-16) A17L Antibody, Human IgG1 (1B4) (Cat. No. A1L-M698) captured on Protein A Chip can bind Monkeypox virus (strain Zaire-96-I-16) A17L Protein, His Tag (Cat. No. A1L-M52H3) with an affinity constant of 7.98 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

Protocol

 
评论(0)
 
ACRO质量管理体系
 
 

背景(Background)

Monkeypox is a rare zoonosis caused by monkeypox virus, which has become the most serious orthpoxvirus and consists of complex double stranded DNA. The pathogenesis of monkeypox is that the virus invades the body from respiratory mucosa, multiplies in lymphocytes, and incurs into blood producing transient venereal toxemia. after the virus multiplies in cells, the cells can invade the blood and propagate to the skin of the whole body, causing lesions. A17L is essential for an early step in virion morphogenesis.

 

前沿进展

Computational identification of monkeypox virus epitopes to generate a novel vaccine antigen against Mpox
Dülek, Mutlu, Koçkaya et al
Biologicals (2024) 88, 101798
Abstract: Monkeypox virus (MPXV) belonging to poxviridae family causes chronic viral disease in various mammals including human and monkeys. Conventional vaccines developed against smallpox of poxviridae, are not specific against Mpox. Also, they can cause various side effects after vaccination. In this study, we aimed to analyze the A17L, A28L, A37R, A43R, E8L, H3L, B6R, and M1R structural proteins of MPXV and identify epitopes in them which can be used to generate vaccine antigens. Among the proteins analyzed, the M1R protein was predicted to be more appropriate for use in vaccine research due to its high antigenicity value and other physicochemical features. Also, A17L, B6R and E8L had high antigenicity values. E8L protein was more conserved while the A37R, A43R, and B6R proteins had signal peptides. Although a total of eight B cell epitopes were predicted in all proteins analyzed, CNGETK epitope belonging to B6R protein had the highest antigenicity value (1.7083), as well as was non-allergenic, non-toxic, and soluble. Based on T cell epitope analyses performed on all proteins, fourteen MHC-I/II epitopes were predicted that are antigenic, non-allergenic and non-toxic, as well as soluble. Among them, MHC-I related-HEIYDRNVGF epitope in A28L protein had the highest antigenicity value (1.6650) and MHC-II related-IGNIKIVQIDIRDIK epitope in A37R protein had the highest antigenicity value (2.0280). In conclusion, eight structural proteins of MPXV were successfully analyzed and 22 important epitopes were identified that could serve as vaccine antigens or in serological studies to develop diagnostic tools.Copyright © 2024 International Alliance for Biological Standardization. Published by Elsevier Ltd. All rights reserved.
Complete Genome Sequencing, Annotation, and Mutational Profiling of the Novel Clade I Human Mpox Virus, Kamituga Strain
Masirika, Kumar, Dutt et al
J Infect Dev Ctries (2024) 18 (4), 600-608
Abstract: Human Mpox (formerly monkeypox) infection is an emerging zoonotic disease caused by the Mpox virus (MPXV). We describe the complete genome annotation, phylogeny, and mutational profile of a novel, sustained Clade I Mpox outbreak in the city of Kamituga in Eastern Democratic Republic of the Congo (DRC).A cross-sectional, observational, cohort study was performed among patients of all ages admitted to the Kamituga Hospital with Mpox infection symptoms between late September 2023 and late January 2024. DNA was isolated from Mpox swabbed lesions and sequenced followed by phylogenetic analysis, genome annotation, and mutational profiling.We describe an ongoing Clade I Mpox outbreak in the city of Kamituga, South Kivu Province, Democratic Republic of Congo. Whole-genome sequencing of the viral RNA samples revealed, on average, 201.5 snps, 28 insertions, 81 deletions, 2 indels, 312.5 total variants, 158.3 amino acid changes, 81.66 intergenic variants, 72.16 synonymous mutations, 106 missense variants, 41.16 frameshift variants, and 3.33 inframe deletions across six samples. By assigning mutations at the proteome level for Kamituga MPXV sequences, we observed that seven proteins, namely, C9L (OPG047), I4L (OPG080), L6R (OPG105), A17L (OPG143), A25R (OPG151), A28L (OPG153), and B21R (OPG210) have emerged as hot spot mutations based on the consensuses inframe deletions, frameshift variants, synonymous variants, and amino acids substitutions. Based on the outcome of the annotation, we found a deletion of the D14L (OPG032) gene in all six samples. Following phylogenetic analysis and whole genome assembly, we determined that this cluster of Mpox infections is genetically distinct from previously reported Clade I outbreaks, and thus propose that the Kamituga Mpox outbreak represents a novel subgroup (subgroup VI) of Clade I MPXV.Here we report the complete viral genome for the ongoing Clade I Mpox Kamituga outbreak for the first time. This outbreak presents a distinct mutational profile from previously sequenced Clade I MPXV oubtreaks, suggesting that this cluster of infections is a novel subgroup (we term this subgroup VI). These findings underscore the need for ongoing vigilance and continued sequencing of novel Mpox threats in endemic regions.Copyright (c) 2024 Leandre Murhula Masirika, Anuj Kumar, Mansi Dutt, Ali Toloue Ostadgavahi, Benjamin Hewins, Maliyamungu Bubala Nadine, Bilembo Kitwanda Steeven, Franklin Kumbana Mweshi, Léandre Mutimbwa Mambo, Justin Bengehya Mbiribindi, Freddy Belesi Siangoli, Alyson A Kelvin, Jean Claude Udahemuka, Patricia Kelvin, Luis Flores, David J Kelvin, Gustavo Sganzerla Martinez.
Showing 1-2 of 2 papers.
Powered by BizGenius
 
 
货号/价格
文档
联系电话:
+86 400-682-2521(全国)
010-53681107(北京)
021-50850665(上海)
运输方式
订单邮箱:
order.cn@acrobiosystems.com
技术支持邮箱:
tech.cn@acrobiosystems.com
前沿进展
点击查看详细

消息提示

请输入您的联系方式,再点击提交!

确定